丹麦男性骨质疏松症流行病学(1996-2018)
这项基于丹麦全国登记数据的队列研究纳入1996-2018年间50岁及以上男性,以医院诊断、骨质疏松性骨折诊断或门诊领取抗骨质疏松药物定义骨质疏松,报告年发病率和患病率,并描述骨折、合并症、社会经济状况及治疗启动情况。共识别171,186名符合标准的男性,年龄标化发病率为8.6/1000人年(95%CI 8.5-8.6),患病率从4.3%升至7.1%,50岁后余生骨质疏松风险接近30%,诊断后1年内启动抗骨质疏松治疗的比例从6.9%升至29.8%。作者认为男性骨质疏松症可能诊断不足且治疗不足,尽管治疗启动率在增加。
要点
- 丹麦50岁以上男性中,每四人就有一人将在50岁后发生骨质疏松,骨折是常见首发表现。
- 骨质疏松年龄标化发病率为8.6/1000人年(95%CI 8.5-8.6),患病率22年间从4.3%升至7.1%。
- 诊断后1年内启动抗骨质疏松治疗的比例从6.9%升至29.8%,但作者认为男性骨质疏松仍可能治疗不足。
核心结论
- 作者认为,尽管治疗启动率在增加,男性骨质疏松症仍可能治疗不足。
研究设计与样本
- 本研究为基于丹麦全国登记数据的队列研究,纳入1996-2018年间居住在丹麦、50岁及以上的男性。
- 骨质疏松定义为满足以下之一:医院骨质疏松诊断、医院骨质疏松性骨折诊断,或门诊领取抗骨质疏松药物。
- 研究共识别171,186名符合骨质疏松研究标准的男性,并报告年发病率和患病率,描述骨折、合并症、社会经济状况及抗骨质疏松治疗启动的分布。
- 研究还在年龄相近的无骨质疏松男性中描述了部分所选特征。
主要发现
- 骨质疏松总体年龄标化发病率为8.6/1000人年(95%CI 8.5-8.6),波动于7.7至9.7之间。
- 22年期间患病率从4.3%(95%CI 4.2-4.3)上升至7.1%(95%CI 7.0-7.1)。
- 50岁后余生发生骨质疏松的风险接近30%。
- 诊断后1年内启动抗骨质疏松治疗的比例从6.9%上升至29.8%。
- 与年龄相近的无骨质疏松男性相比,骨质疏松男性合并症更多且领取的药物更多。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Osteoporosis in men may be underdiagnosed. One in four men in Denmark will develop osteoporosis after age of 50 years, with fracture as a common presenting symptom. PURPOSE: The aim of this study was to describe epidemiology of male osteoporosis in Denmark. METHODS: In this nationwide registry-based cohort study, we identified men with osteoporosis, 50 years or older, residing in Denmark, during the years 1996-2018. Osteoporosis was defined as one of the following: a hospital diagnosis of osteoporosis; a hospital diagnosis of osteoporosis fracture; or an outpatient dispensing of an anti-osteoporosis medication. We reported annual incidence and prevalence and described the distribution of fractures, comorbidities, socioeconomic status, and initiation of anti-osteoporosis therapy among men with osteoporosis. Selected characteristics were also described among men without osteoporosis of similar age. RESULTS: There were 171,186 men fulfilling the study criteria for osteoporosis. The overall age-standardized incidence rate of osteoporosis was 8.6 per 1000 person-years (95% confidence interval (CI), 8.5-8.6), varying between 7.7 and 9.7, while the prevalence increased from 4.3% (95% CI, 4.2-4.3) to 7.1% (95% CI, 7.0-7.1) during the 22-year period. The remaining-lifetime risk of developing osteoporosis after age of 50 years was close to 30%. The proportion of men initiating anti-osteoporosis treatment within 1 year of diagnosis increased from 6.9% to 29.8%. Men with osteoporosis had more comorbidities and redeemed more medication than did men without osteoporosis of similar age. CONCLUSION: Osteoporosis among men may be undertreated despite increasing treatment initiation.
引用
- Bruhn R, Pedersen AB, Heide-Jørgensen U, et al. Epidemiology of male osteoporosis in Denmark (1996-2018). Osteoporos Int. 2023. PMID: 36912928. doi:10.1007/s00198-023-06720-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。